{"filings":[{"id":591756,"accession_number":"0001193125-26-235517","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-05-22T12:11:43+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer Board Unanimously Rejects $2.40/Share Cash Plus CVR Bid from Radoff-JEC Group","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Board unanimously rejected May 14 revised proposal at $2.40/share cash plus contingent value right.","Proposal implies equity value below sum of Seer's cash, cash equivalents and investments.","Board determined proposal significantly undervalues Seer's long-term growth prospects.","Proposal is materially the same as the one rejected by the Board on April 27, 2026.","Seer advised by Perella Weinberg Partners and Wilson Sonsini Goodrich & Rosati."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68644,"accession_number":"0001193125-26-221696","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-05-13T20:19:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 2026 revenue $2.8M (-34% YoY); reaffirms FY2026 guidance of $16M-$18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.8M, down 34% from $4.2M YoY, driven by depressed academic funding and competitive activity.","Net loss $16.8M vs $19.9M prior year; operating expenses down 20% to $18.2M.","Reaffirmed full year 2026 revenue guidance of $16M-$18M (3% growth at midpoint).","Ended Q1 with ~$220M cash and investments; repurchased ~1.5M shares in the quarter.","Appointed Anthony (Tony) Bazarko as CCO; secured collaboration with Precision Health Research, Singapore (10,000 samples)."],"consensus_eps_estimate":-0.3009,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2793000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95026,"accession_number":"0001193125-26-204084","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer appoints Anthony Bazarko as Chief Commercial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Bazarko named CCO effective May 4, 2026; previously President & CEO of Biologos and CCO at Specific Diagnostics.","Bazarko brings over 20 years of commercial leadership in life sciences, diagnostics, and biotech.","He will lead Seer's Sales, Marketing, and Customer Experience to accelerate Proteograph Product Suite adoption.","CEO Omid Farokhzad cites Bazarko's record of commercial strategy as key to next growth phase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95025,"accession_number":"0001193125-26-182155","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer Board unanimously rejects revised $2.35/share takeover bid from Radoff-JEC Group","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Revised proposal from Radoff/JEC offers $2.35/share plus contingent value right; board says significantly undervalues Seer.","Board claims implied equity value is below Seer's current cash, cash equivalents and investments.","Seer highlights 240 patent filings, 80+ peer-reviewed publications, and SGK100 biobank study as evidence of momentum.","Board will evaluate Radoff-JEC's director nominees per bylaws; no action required from stockholders now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95024,"accession_number":"0001193125-26-152998","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Seer receives unsolicited $2.25/share buyout proposal from Radoff-JEC Group","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Radoff-JEC Group proposed to acquire all Seer shares for $2.25 per share cash plus a contingent value right.","Board will review the unsolicited, non-binding proposal with financial and legal advisors.","Radoff-JEC Group nominated three director candidates for election at the 2026 annual meeting.","No stockholder action required now; formal Board recommendation to be included in proxy statement.","2026 Annual Meeting date has not yet been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107802,"accession_number":"0001193125-26-131802","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PTAB upholds 23 claims of Seer's particle proteomics patent in Bruker challenge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["PTAB Final Written Decision on March 23, 2026, upholds five challenged and 18 unchallenged claims of U.S. Patent No. 11,435,360.","Patent covers protein enrichment using engineered nano- and microparticles, core to Seer's Proteograph platform.","Petitioners PreOmics GmbH and Biognosys AG (Bruker subsidiaries) failed to show unpatentability of claims 2,3,7,23,24.","Six claims (1,4,6,22,24,25) were found unpatentable; appeal deadline is May 25, 2026.","'360 patent is owned by Brigham and Women's Hospital and exclusively licensed to Seer; CEO vows continued IP defense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107801,"accession_number":"0001193125-26-107335","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Seer amends Tax Benefit Preservation Plan, pays $250K mootness fee to settle suit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Amended definition of 'Beneficial Ownership' in Tax Benefit Preservation Plan to address stockholder lawsuit.","Lawsuit Taylor v. Farokhzad (Del. Chancery) challenged Plan's definition; company believes allegations meritless.","Agreed to pay $250,000 mootness fee to avoid litigation costs; Delaware Action to be dismissed as moot.","Amendment clarifies interaction with Treasury Regulation § 1.382-3(a)(1); effective March 13, 2026.","Settlement fully satisfies all claims for attorneys' fees, costs, and expenses in the Delaware Action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107800,"accession_number":"0001193125-26-076684","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Seer adopts tax-benefit preservation plan (poison pill) to protect NOLs; triggers at 4.9% ownership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declared dividend of one Right per common share, record date March 9, 2026.","Rights become exercisable at $11.00 each for 1/1000th Series A Preferred after trigger.","Plan deters acquisition of 4.9% or more common stock without Board approval.","Plan expires on February 25, 2029, unless extended or NOLs are fully utilized.","Adopted to preserve net operating losses and tax attributes under Section 382 of the Code."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107799,"accession_number":"0001193125-26-076580","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q4 revenue $4.2M (+5% YoY); FY 2026 guidance $16-18M implies ~3% midpoint growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $4.2M, up 5% YoY from $4.0M; product revenue $2.8M, service $1.2M.","Full-year 2025 revenue $16.6M (+17% YoY vs $14.2M); net loss $73.6M, improved from $86.6M.","Installed base reached 82 instruments (+67% YoY); 33 instruments placed in FY 2025.","Cash & investments $240.6M at Dec 31, 2025; operating expenses down 23% in Q4 to $19.6M.","FY 2026 revenue guidance $16M-$18M; CEO cites persistent NIH funding uncertainty as headwind."],"consensus_eps_estimate":-0.3264,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":16578000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124202,"accession_number":"0001193125-25-317535","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Seer converts all Class B stock to Class A, ending dual-class voting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All outstanding Class B shares automatically converted into Class A on a 1:1 basis at close of business Dec. 9, 2025.","Following conversion, Class B shares retired; authorized capital reduced via Certificate of Retirement filed Dec. 12, 2025.","Each prior Class B share had ten votes; now holders have one vote per share under Class A.","Economic interests unchanged; stock continues trading on Nasdaq under ticker SEER."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124201,"accession_number":"0001193125-25-269705","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 2025 revenue $4.1M, net loss $18.2M; reaffirms FY25 revenue guidance $17-18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.1M (+2% YoY); product revenue $2.8M, service revenue $1.2M, including $300K related party.","Gross margin 51%; operating expenses $21.5M (down 18% YoY) driven by lower stock-based comp and costs.","Net loss $18.2M vs $21.3M Q3 2024; cash, equivalents and investments $251.2M.","Shipped nearly 3x instruments in first 9 months of 2025 compared to all of 2024; record publications.","FY2025 revenue guidance reaffirmed at $17M-$18M, representing ~24% growth at midpoint over FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":12377000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140863,"accession_number":"0001726445-25-000006","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer appoints Isaac Ro to Board of Directors; grants initial equity award","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Isaac Ro appointed to Seer board effective Sept 2, 2025, also named to Audit Committee as financial expert.","Initial equity award granted: option for 61,000 shares and RSU for 41,000 shares, vesting over 3 years.","Ro is Partner at Catalio Capital Management; previously CFO at Sema4 and Thrive Earlier Detection.","Appointment resolves any potential non-compliance with Nasdaq listing rules regarding audit committee financial expert."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140862,"accession_number":"0000950170-25-104072","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 revenue $4.1M (+32% YoY); launches Proteograph ONE & SP200","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $4.1M for Q2 2025, up 32% from $3.1M a year ago, driven by product and service revenue.","Net loss narrowed to $19.4M from $22.9M; operating expenses down 21% to $22.6M.","Cash, equivalents and investments of $263.3M as of June 30, 2025.","Full-year 2025 revenue guidance reaffirmed at $17M-$18M (24% midpoint growth).","Launched high-throughput Proteograph ONE assay and SP200 automation instrument."],"consensus_eps_estimate":-0.3774,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":8256000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140861,"accession_number":"0000950170-25-094597","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Seer non-compliant with Nasdaq Audit Committee rule after annual meeting; cure period sought","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 7, 2025, notified Nasdaq that post-annual meeting it will not comply with Rule 5605(c)(2)(A) requiring at least three Audit Committee members, one with financial sophistication.","Intends to rely on cure period under Rule 5605(c)(4)(B) and expects to regain compliance before expiration.","Annual meeting elected all six director nominees: Farokhzad, Gulyani, McGuire, Langer, Nishar, Roelofs (withheld votes ranged from 0.6M to 10.0M).","Stockholders ratified Deloitte & Touche as independent auditor for FY2025 with 85.9M votes for, 4,444 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158603,"accession_number":"0000950170-25-070359","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 revenue $4.2M (+37% YoY); ships as many instruments as all of 2024; reaffirms FY25 guidance $17-18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.2M, up 37% from $3.1M YoY, driven by higher product sales and service revenue.","Net loss $19.9M vs $20.7M YoY; operating expenses down 14% to $22.8M.","Cash, equivalents and investments ~$285M at quarter end.","Q1 instrument shipment volume equaled full-year 2024; 10,000-sample contract with new customer announced.","Full-year 2025 revenue guidance reaffirmed at $17M-$18M (24% growth at midpoint)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":4205000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177008,"accession_number":"0000950170-25-029140","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q4 revenue down 10% YoY to $4.0M; full-year net loss $86.6M; guides 2025 rev $17-18M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $4.0M (-10% YoY); full-year 2024 revenue $14.2M (-15% YoY).","Q4 net loss $21.7M vs $17.8M YoY; full-year net loss $86.6M vs $86.3M.","Shipped 10 instruments in 2024; cumulative 72. Ended with ~$300M cash/investments.","Repurchased ~6.5M shares at avg $1.82/share in 2024, reducing shares by ~10%.","Expects 2025 revenue $17-18M, representing ~24% growth at midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":14170000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193790,"accession_number":"0000950170-24-122309","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q3 2024 revenue $4.0M, net loss $21.3M; FY guidance reaffirmed $13-15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $4.0M vs $4.2M YoY (down 3%); product revenue $3.1M, service $847K, grant $90K.","Net loss $21.3M vs $21.1M YoY; gross margin 48%; operating expenses down 6% to $26.3M.","Repurchased 3.7M shares at avg $1.78 in Q3; total 5.7M shares repurchased to date.","Entered co-marketing agreement with Thermo Fisher Scientific for Proteograph suite with Orbitrap Astral mass specs.","Cash, equivalents & investments $312M; FY 2024 revenue guidance reaffirmed at $13-15M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":10170000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193789,"accession_number":"0000950170-24-112982","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer reprices ~7.9M underwater options to $2.00; CEO/CFO affected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repricing of ~7.9M underwater options (original strike $2.08-$60.15) to $2.00 per share.","CEO Omid Farokhzad repriced options on 2,732,470 shares; CFO David Horn on 1,140,454 shares.","Performance-based options with $6.89 hurdle amended to $3.00 (150% of $2.00) for 790,000 shares.","Repriced options have retention period through Apr 4, 2026; early exercise triggers original premium price.","Board decided no additional equity awards in 2025 to executive officers SVP and above."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210122,"accession_number":"0000950170-24-098074","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seer appoints Nicolas Roelofs to board as Lead Independent Director effective Aug 13, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Roelofs replaces David Hallal as Lead Independent Director and joins CG&N and Science & Technology committees.","Initial equity award of 69,470 stock options and 46,886 RSUs, vesting in three equal annual installments.","Roelofs brings 35+ years experience including president of Agilent Life Sciences Group.","No arrangement or understanding with any person regarding his election as director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210121,"accession_number":"0000950170-24-094022","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q2 revenue $3.1M (-23% YoY); FY 2024 guidance cut to $13-15M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M, down 23% YoY from $4.0M; product revenue $2.2M, service $845K.","Net loss $22.9M vs $23.4M prior year; operating expenses $28.8M (down 5% YoY).","Full-year 2024 revenue guidance reduced to $13M-$15M from prior $16M-$18M.","Launched Seer Technology Access Center (STAC) in Europe; customer papers in Nature.","Cash, equivalents and investments $344.6M as of June 30, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":6138000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210120,"accession_number":"0000950170-24-084935","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Seer CLO resigns; David Hallal appointed to Audit Committee, resolving Nasdaq compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elona Kogan resigns as Chief Legal Officer and Corporate Secretary effective July 26, 2024; departure not related to any disagreement.","David Hallal appointed to Audit Committee on July 19, 2024; qualifies as audit committee financial expert.","Appointment follows Rachel Haurwitz's resignation from Board, which caused non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).","Company believes Hallal's appointment resolves potential non-compliance with Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210119,"accession_number":"0000950170-24-083207","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seer director resigns; company out of compliance with Nasdaq Audit Committee rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dr. Rachel Haurwitz resigned from Seer's Board and all committees effective July 8, 2024.","Company notified Nasdaq on July 11 that it no longer meets Listing Rule 5605(c)(2)(A) for Audit Committee.","Seer intends to rely on cure period under Rule 5605(c)(4)(B) and is evaluating board composition to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228360,"accession_number":"0000950170-24-073743","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Seer stockholders elect four directors and ratify Deloitte as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Quorum achieved with 82.8M votes representing 81.7% of eligible votes.","Elected Omid Farokhzad, Meeta Gulyani, David Hallal, Terrance McGuire; each >66M votes for.","Ratified Deloitte & Touche LLP as auditor for FY2024; 82.7M for, 23.8K against, 69.8K abstain.","All proposals passed; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228359,"accession_number":"0000950170-24-055694","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer Q1 revenue down 24% YoY to $3.1M; net loss narrows to $20.7M; authorizes $25M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.1M (-24% YoY); product revenue $2.5M (incl. $828K related party), service $534K.","Net loss $20.7M improved from $24.0M; gross margin 44%; operating expenses $26.6M (-10% YoY).","Cash and investments $359.2M; board authorized up to $25M share repurchase program.","FY2024 revenue guidance of $16M-$18M, essentially flat vs FY2023 revenue.","Expanding Proteograph STAC program to Europe; three new peer-reviewed publications supporting platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":3066000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247070,"accession_number":"0000950170-24-023099","cik":1726445,"company_name":"Seer, Inc.","ticker":"SEER","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seer reports Q4 revenue down 4% YoY to $4.4M; FY revenue up 8% to $16.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $17.8M narrowed from $22.5M; FY net loss $86.3M vs $93.0M prior year.","Cash, equivalents and investments totaled $373.1M as of Dec 31, 2023.","FY 2024 revenue guided to $18M-$20M, representing ~14% growth at midpoint.","Cumulative instruments shipped reached 62; 23 shipped in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":16661000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":104464948.51851851,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}